Hisamitsu Pharmaceutical Co Inc
TSE:4530
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 636
4 562
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Hisamitsu Pharmaceutical Co Inc
Hisamitsu Pharmaceutical Co Inc
Total Current Liabilities
Hisamitsu Pharmaceutical Co Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hisamitsu Pharmaceutical Co Inc
TSE:4530
|
Total Current Liabilities
¥58.6B
|
CAGR 3-Years
23%
|
CAGR 5-Years
10%
|
CAGR 10-Years
2%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Total Current Liabilities
¥2.4T
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Total Current Liabilities
¥643.9B
|
CAGR 3-Years
24%
|
CAGR 5-Years
14%
|
CAGR 10-Years
5%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Total Current Liabilities
¥747B
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Total Current Liabilities
¥239B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Total Current Liabilities
¥1.1T
|
CAGR 3-Years
25%
|
CAGR 5-Years
18%
|
CAGR 10-Years
11%
|
|
Hisamitsu Pharmaceutical Co Inc
Glance View
In the bustling landscape of Japanese pharmaceutical companies, Hisamitsu Pharmaceutical Co., Inc. stands out with its pioneering spirit and deep-rooted dedication to health and wellness. Founded in 1847, the company has evolved over a century and a half, transitioning from a modest establishment selling herbal medicines to a globally recognized manufacturer of pain-relief products. At the core of Hisamitsu's operations is its flagship product, the transdermal patch, featuring the SALONPAS brand as its crown jewel. This innovative delivery system allows active medicinal ingredients to penetrate the skin, addressing pain at its source effectively and efficiently. As global demand for non-invasive pain relief grows, Hisamitsu leverages its expertise in transdermal technology, continuously innovating and expanding its product line to cater to diverse consumer needs. Hisamitsu's success hinges on a solid blend of cutting-edge research, consistent quality, and strategic marketing prowess. By investing heavily in R&D, the company not only enhances its existing product offerings but also explores new therapeutic areas, ensuring a pipeline poised for future growth. Besides Japan, Hisamitsu's market presence extends across the Americas, Europe, and Asia, with international sales contributing significantly to its revenue stream. The company is adept at navigating intricate regulatory landscapes and varying consumer preferences to establish its footprint globally. This strategic expansion, coupled with a relentless commitment to quality, enables Hisamitsu to sustain its profitability while fulfilling its mission of delivering comfort and improved quality of life to people around the world.
See Also
What is Hisamitsu Pharmaceutical Co Inc's Total Current Liabilities?
Total Current Liabilities
58.6B
JPY
Based on the financial report for Aug 31, 2024, Hisamitsu Pharmaceutical Co Inc's Total Current Liabilities amounts to 58.6B JPY.
What is Hisamitsu Pharmaceutical Co Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
2%
Over the last year, the Total Current Liabilities growth was 8%. The average annual Total Current Liabilities growth rates for Hisamitsu Pharmaceutical Co Inc have been 23% over the past three years , 10% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
